Investor
Catalys Pacific, LLC
CIK 0002011385 · filed 2026-05-14 · SEC filing
13F book
$230.7M
Positions
2
Largest name
92.8%
Mineralys Therapeutics, Inc. · MLYS
Est. mark
−$80.5M
Price effect on 2 names still held. Flow $720.4K.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. | MLYS | 7.9M | $214.1M | 92.8% | −$72.7M | Held |
| Phathom Pharmaceuticals, Inc. | PHAT | 1.49M | $16.6M | 7.2% | −$7.83M | Added−$7.11M |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.